SHR1032

SHR1032 is a **novel small molecule non-cyclic di-nucleotide STING agonist** designed to activate the stimulator of interferon genes (STING) pathway, resulting in the induction of type I interferons (notably interferon β), tumor necrosis factor α, and interleukin-6, thereby stimulating anti-tumor immune responses and causing direct cell death in acute myeloid leukemia (AML) cells. SHR1032 has shown superior efficacy compared to first-generation cyclic di-nucleotide STING agonists (like ADU-S100), displaying robust activation across various human STING haplotypes and yielding strong anti-tumor effects in preclinical models, including significant tumor growth inhibition in MC38 murine syngeneic tumor models[1][2][3][4][5][9]. Its mechanism involves cGAS-STING pathway activation, leading to potent immunomodulation and direct cytotoxicity in AML. This molecule is still in preclinical/early clinical investigation as a promising immunotherapeutic agent for both solid tumors and hematological malignancies.

Other names

SHR1032SHR-1032SHR 1032